close
close

Illumina (NASDAQ:ILMN) Stock Rating Upgraded by Citigroup

Illumina (NASDAQ:ILMN) Stock Rating Upgraded by Citigroup

Citigroup raises shares Enlightenment (NASDAQ:ILMNFree Report) It was upgraded to a buy rating from a neutral rating in a report released on Wednesday, Marketbeat.com According to reports, they currently have a price target of $140.00 for shares of the life sciences company.

ILMN has been the subject of a number of other research reports. Robert W. Baird raised his price target on Illumina from $125.00 to $128.00 and gave the stock a neutral rating in a research note on Friday, May 3rd. StockNews.com The market began coverage on Illumina in a research report on June 30. They issued a buy rating on the stock. Evercore ISI lowered their price target on shares of Illumina from $195.00 to $175.00 and set an outperform rating on the company in a research report on Tuesday, June 11. Barclays raised their target price on shares of Illumina from $85.00 to $100.00 and gave the company an underweight rating in a report on Wednesday, April 10. Finally, Royal Bank of Canada lowered their price target on shares of Illumina from $249.00 to $242.00 and set an outperform rating on the company in a report on Monday, July 1. Two research analysts rated the stock with a sell rating, ten gave a hold rating, and ten gave a buy rating to the company’s stock. The stock’s current consensus rating is Hold and its consensus target price is $158.57, according to MarketBeat.

Check out our latest stock analysis on ILMN

Illumina Shares Up 6.1%

ILMN It opened at $113.17 on Wednesday. The stock’s fifty-day moving average is $109.11, and its 200-day moving average is $125.83. The company’s market cap is $18.03 billion, with a P/E ratio of -13.89 and a beta of 1.15. Illumina has a fifty-two-week low of $89.00 and a fifty-two-week high of $195.64. The company’s debt-to-equity ratio is 0.26, a liquidity ratio of 1.36 and a current ratio of 1.75.

Enlightenment (NASDAQ:ILMNGet a Free Report) released its latest-quarter earnings data on Thursday, May 2. The life sciences company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. The company earned $0.08 EPS in the same quarter a year ago. The business’ revenue was down 1.0% from the prior-year period. On average, equities analysts expect Illumina to report 0.98 EPS for the current year.

Illumina’s Institutional Business

A number of institutional investors and hedge funds have recently bought and sold stocks. Park Avenue Securities LLC increased its stake in Illumina by 61.3% in the 2nd quarter. Park Avenue Securities LLC now owns 9,186 shares of the life sciences company worth $959,000 after purchasing an additional 3,492 shares during the period. Kingswood Wealth Advisors LLC increased its stake in Illumina shares by 12.7% in the 2nd quarter. Kingswood Wealth Advisors LLC now owns 6,557 shares of the life sciences company worth $684,000 after purchasing an additional 738 shares during the period. Mather Group LLC increased its stake in Illumina by 1,319.6% in the 2nd quarter. Mather Group LLC. It now owns 1,377 shares of the life sciences company’s stock worth $144,000 after purchasing an additional 1,280 shares in the last quarter. Versant Capital Management Inc increased its position in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the period. Finally, DNB Asset Management AS increased its position in Illumina by 10.9% in the 2nd quarter. DNB Asset Management AS owns 27,164 shares of the life sciences company’s stock worth $2,835,000 after purchasing an additional 2,679 shares during the period. 89.42% of the stock is currently held by institutional investors and hedge funds.

About Illumina

(Get a Free Report)

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom and internationally. It operates through its Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, such as reagents, flow cells and library preparation; whole genome sequencing kits of various sizes and complexities; and targeted resequencing kits that sequence exomes, specific genes, and RNA or other genomic regions of interest.

see also

Get News and Ratings for Illumina Daily – Enter your email address below to sign up for MarketBeat.com’s FREE daily email newsletter and get a concise daily summary of the latest news and analyst ratings on Illumina and related companies.